Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its
potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted
to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal
women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer
and who are high or moderate risk of fragility fracture. It is also conducted to determine
the effects of anastrozole on bone mineral density (BMD) and on bone metabolism in women at
low risk of fragility fracture.